Manchester Science Partnerships (MSP) invests in the future with £60m Citylabs expansion

Manchester Science Partnerships (MSP), the UK’s leading science and technology park operator, is to invest £60m in a major expansion of Citylabs, its biomedical centre of excellence in a joint venture partnership with Central Manchester University Hospitals NHS Foundation Trust (CMFT).

In a major vote of confidence for the Manchester city region, the development will create Citylabs 2.0 and Citylabs 3.0 on the CMFT campus, in the heart of Manchester’s Innovation District – Corridor Manchester.

The new development will provide additional space to enable biomedical companies to grow and co-create new health products, in collaboration with the NHS and academia for the benefit of patients.

It is anticipated that when both are completed and fully let Citylabs 2.0 and 3.0 will bring additional economic growth in excess of £100 million and over 750 new jobs to the city.

The project is the first to be delivered by the Strategic Property Partnership between MSP’s parent company, Bruntwood, and CMFT. Announced in March 2016, the partnership will support the delivery of clinical care, research and innovation, as well as the future development of CMFT’s estate.

Rowena Burns, Chief Executive of Manchester Science Partnerships said: “It is entirely fitting that we are making this announcement as part of ESOF- an international event which is focused on innovation and collaboration – two of the pillars on which our business is built.

“Manchester’s Innovation District will be strengthened further by the development of Citylabs 2.0 and 3.0. Our investment will help create fresh ideas, partnerships and scientific discovery. Above all, Manchester and the North West offer investors outstanding access to talent, knowledge and clinical facilities.”

Steve Mycio OBE, Chairman of Central Manchester University Hospitals NHS Foundation Trust added:

By working together in this way with industry, the NHS can ensure health technologies are developed that deliver better outcomes more efficiently to meet current and future needs of our patients and healthcare providers.

“Citylabs 2.0 and 3.0 is our first scheme under the Strategic Property Partnership that CMFT has formed with Bruntwood.  Its purpose is to help ensure that our hospital building and facilities are developed in a flexible and modern way to facilitate early access to new diagnostics and treatments.

“Earlier this year our campus received designation as a Life Sciences Enterprise Zone. This will make Citylabs and our campus an even more attractive place for business, especially spin outs from the hospitals and universities.”

Chris Oglesby, Chairman of Manchester Science Partnerships and Chief Executive of Bruntwood added: “It is great to see our pioneering Strategic Property Partnership with the NHS in Manchester hitting the ground running.

“Our investment in Citylabs 1.0 has been a huge success and we are confident that Citylabs 2.0 and 3.0 will be similarly well received by businesses centred in bio-medical research and innovation.

“Manchester’s excellent connectivity, universities and talent pool, combined with its spirit of enterprise means the city is well placed to thrive in the coming years and we are determined to be at the heart of this journey.”

Sir Richard Leese, Leader of Manchester City Council said: “Citylabs epitomises Manchester’s proud tradition of cutting edge research, one of our distinctive strengths.

“This major investment sends out a resounding message that we remain an outward and forward-looking city in which those who want to invest and create jobs can flourish.”

Citylabs 1.0, which opened in September 2014 after a £25m redevelopment, was fully let within 15 months of opening. It is on track to generate more than 400 new jobs and contribute an estimated £60 million a year to Manchester’s economy.

The investment for the new development will be made in two phases, subject to planning consent being received by the end of this year.

Citylabs 2.0 and 3.0 will be located on the corner of Oxford Road and Hathersage Road, opposite Whitworth Park, at the southern gateway to Europe’s largest clinical-academic campus.

The £25m Citylabs 2.0 development will comprise 85,000 sq ft of lab and office space and subject to planning permission being granted. Construction work will begin in spring 2017, with completion expected in summer 2018.

Citylabs 3.0 will include both the development of new buildings and integration with Old Saint Mary’s Hospital, an existing listed Victorian building, comprising 100,000 sq ft. Construction is planned to start in Summer 2018 and is due to be completed in 2020.

The £35m project includes the restoration of a currently unused former chapel on the site, which is ear-marked for a café/ dining area with the potential for meeting room facilities, as well as extensive external landscaping and the provision of new gardens for the enjoyment of Citylabs occupiers and other users of the hospital facilities.

ENDS

For more information please contact Influential: Chris Hulme on 07971 350116 or Jonathan Daly on 07881 301437

Notes for Editors

The creation of the strategic property partnership between Central Manchester University Hospitals NHS Foundation Trust and Bruntwood is the result of a competitive open tender process. Read more.

Manchester Science Partnerships (MSP) is a Manchester based public-private partnership and the UK’s leading science and technology park operator. MSP owns and operates 3m sq ft of office and laboratory space on its three main campuses – central Manchester, Citylabs 1.0 and Alderley Park.

MSP provides the right environments for innovation to flourish – supporting the growth of companies in the biomedical, ICT, industrial technologies, and digital/creative sectors, ranging in size from start-ups to European HQs and international centres of R&D excellence.

MSP’s network of connections between innovators, scientists, investors and entrepreneurs brings businesses and people together to transform ideas into commercial reality.

MSP’s shareholders are Bruntwood Ltd, The University of Manchester, Manchester Metropolitan University, Central Manchester University Hospitals NHS Foundation Trust and Manchester, Cheshire East and Salford City Councils. See more.

Central Manchester University Hospitals NHS Foundation Trust is a leading provider of specialist healthcare services in Manchester, treating more than a million patients every year. Its seven specialist hospitals (Manchester Royal Infirmary, Saint Mary’s Hospital, Royal Manchester Children’s Hospital, Manchester Royal Eye Hospital, University Dental Hospital of Manchester, Trafford General and Altrincham Hospitals) and community services are home to hundreds of world class clinicians and academic staff committed to finding patients the best care and treatments.  .  The Trust also operates a Medtech Centre in a joint venture with MSP and TRUSTECH that provides access to the Trusts clinical and management expertise to help business to accelerate their development. See more.